Sanofi is divesting its Opella division, valued at €15bn, to focus on core products. Opella, headquartered in France, operates in 100 countries and has over 11,000 employees. The deal aligns with Sanofi's strategy for innovative medicines. The FDA approved Sanofi's Dupixent for COPD, marking a significant advancement in treatment options for patients. Teljes cikk (Euronews.com)